ArticleiScience2026
HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term health burden of SARS-CoV-2 infections remains poorly understood. In a cohort from Vancouver, Canada, we identified immune imprinting to endemic β-human coronaviruses (HCoVs), reflected by affinity-matured IgG responses that cross-reacted with the SARS-CoV-2 spike with low affinity, along with an early expansion of memory B cells recognizing HKU1 and the conserved S2 domain following the first dose of ancestral-strain vaccination. Vaccination also enhanced antibody-dependent cellular phagocytosis (ADCP), primarily directed against the HKU1 spike and SARS-CoV-2 S2 domains. In another cohort from the same region, higher HKU1 spike IgG levels and increased antibody-dependent complement deposition (ADCD) were associated with a greater likelihood of post-COVID symptoms, even though these individuals had experienced fewer SARS-CoV-2 infections at the one-year follow-up. Together, these findings suggest that β-HCoV-associated immune imprinting may simultaneously reduce infection risk and promote pathological Fc-mediated inflammation, potentially contributing to post-COVID conditions following infection with contemporary SARS-CoV-2 variants in individuals vaccinated against earlier strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.